Progression in attenuating myocardial reperfusion injury: An overview

被引：50

作者：

Bernink, F. J. P. ^{[1
]}

Timmers, L. ^{[2
]}

Beek, A. M. ^{[1
]}

Diamant, M. ^{[3
]}

Roos, S. T. ^{[1
]}

Van Rossum, A. C. ^{[1
]}

Appelman, Y. ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Med Ctr, Dept Cardiol, Amsterdam, Netherlands

[2] Univ Med Ctr Utrecht, Dept Cardiol, Utrecht, Netherlands

[3] Vrije Univ Amsterdam, Med Ctr, Dept Internal Med, Ctr Diabet, Amsterdam, Netherlands

来源：

INTERNATIONAL JOURNAL OF CARDIOLOGY | 2014年 / 170卷 / 03期

关键词：

Myocardial infarction; Percutaneous coronary intervention; Myocardial reperfusion injury; GLUCOSE-INSULIN-POTASSIUM; GLUCAGON-LIKE PEPTIDE-1; PERCUTANEOUS CORONARY INTERVENTION; ATRIAL-NATRIURETIC-PEPTIDE; REDUCES INFARCT SIZE; LEFT-VENTRICULAR DYSFUNCTION; PRIMARY ANGIOPLASTY; INTRACORONARY ADENOSINE; HYPEROXEMIC REPERFUSION; THROMBOLYTIC THERAPY;

D O I：

10.1016/j.ijcard.2013.11.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Reperfusion by means of percutaneous coronary intervention or thrombolytic therapy is the most effective treatment for acute myocardial infarction, markedly reducing mortality and morbidity. Reperfusion however induces necrotic and apoptotic damages to cardiomyocytes, that were viable prior to reperfusion, a process called lethal reperfusion injury. This process, consisting of many single processes, may be responsible of up to half of the final infarct size. A myriad of therapies as an adjunct to reperfusion have been studied with the purpose to attenuate reperfusion injury. The majority of these studies have been disappointing or contradicting, but recent proof-of-concept trials show that reperfusion injury still is a legitimate target. This overview will discuss these trials, the progression in attenuating myocardial reperfusion injury, promising therapies, and future perspectives. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：261 / 269

页数：9

共 94 条

[1] Controversies in Cardiovascular MR Imaging: Reasons Why Imaging Myocardial T2 Has Clinical and Pathophysiologic Value in Acute Myocardial Infarction [J].

Arai, Andrew E. ;

Leung, Steve ;

Kellman, Peter .

RADIOLOGY, 2012, 265 (01) :23-32

[2]

Armstrong PW, 2007, JAMA-J AM MED ASSOC, V297, P43

[3] Rationale and Design of the 'MITOCARE' Study: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of TRO40303 for the Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction [J].

Atar, Dan ;

Abitbol, Jean-Louis ;

Arheden, Hakan ;

Berdeaux, Alain ;

Bonnet, Jean-Louis ;

Carlsson, Marcus ;

Clemmensen, Peter ;

Cuvier, Valerie ;

Danchin, Nicolas ;

Dubois-Rande, Jean-Luc ;

Engblom, Henrik ;

Erlinge, David ;

Firat, Huseyin ;

Jensen, Svend Eggert ;

Halvorsen, Sigrun ;

Hansen, Henrik Steen ;

Heiberg, Einar ;

Larsen, Alf-Inge ;

Le Corvoisier, Philippe ;

Longlade, Pascal ;

Nordrehaug, Jan Erik ;

Perez, Carole ;

Pruss, Rebecca ;

Sonou, Gilles ;

Schaller, Sophie ;

Tuseth, Vegard ;

Vicaut, Eric .

CARDIOLOGY, 2012, 123 (04) :201-207

[4] Results of the first clinical study of adjunctive caldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction:: the randomized multicentre CASTEMI study [J].

Bar, Frits W. ;

Tzivoni, Dan ;

Dirksen, Maurits T. ;

Fernandez-Ortiz, Antonio ;

Heyndrickx, Guy R. ;

Brachmann, Johannes ;

Reiber, Johan H. C. ;

Avasthy, Neelima ;

Tatsuno, Jun ;

Davies, Martin ;

Hibberd, Mark G. ;

Krucoff, Mitchell W. .

EUROPEAN HEART JOURNAL, 2006, 27 (21) :2516-2523

[5] Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction: The EXAMI study [J].

Bernink, Flip J. P. ;

Timmers, Leo ;

Diamant, Michaela ;

Scholte, Martijn ;

Beek, Aernout M. ;

Kamp, Otto ;

Marques, Koen M. J. ;

Denham, Robert N. ;

Chen, Weena J. Y. ;

Doevendans, Pieter A. ;

van Rossum, Albert C. ;

van Royen, Niels ;

Horrevoets, Anton J. G. ;

Appelman, Yolande .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (01) :289-290

[6] Myocardial protection at a crossroads - The need for translation into clinical therapy [J].

Bolli, R ;

Becker, L ;

Gross, G ;

Mentzer, R ;

Balshaw, D ;

Lathrop, DA .

CIRCULATION RESEARCH, 2004, 95 (02) :125-134

[7] Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury [J].

Bose, AK ;

Mocanu, MM ;

Carr, RD ;

Brand, CL ;

Yellon, DM .

DIABETES, 2005, 54 (01) :146-151

[8] Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial [J].

Botker, Hans Erik ;

Kharbanda, Rajesh ;

Schmidt, Michael R. ;

Bottcher, Morten ;

Kaltoft, Anne K. ;

Terkelsen, Christian J. ;

Munk, Kim ;

Andersen, Niels H. ;

Hansen, Troels M. ;

Trautner, Sven ;

Lassen, Jens Flensted ;

Christiansen, Evald Hoj ;

Krusell, Lars R. ;

Kristensen, Steen D. ;

Thuesen, Leif ;

Nielsen, Soren S. ;

Rehling, Michael ;

Sorensen, Henrik Toft ;

Redington, Andrew N. ;

Nielsen, Torsten T. .

LANCET, 2010, 375 (9716) :727-734

[9] The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis [J].

Burns, RJ ;

Gibbons, RJ ;

Yi, QL ;

Roberts, RS ;

Miller, TD ;

Schaer, GL ;

Anderson, JL ;

Yusuf, S .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (01) :30-36

[10] Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: Results of a randomized multicenter Pol-GIK trial [J].

Ceremuzynski, L ;

Budaj, A ;

Czepiel, A ;

Burzykowski, T ;

Achremczyk, P ;

Smielak-Korombel, W ;

Maciejewicz, J ;

Dziubinska, J ;

Nartowicz, E ;

Kawka-Urbanek, T ;

Piotrowski, W ;

Hanzlik, J ;

Cieslinski, A ;

Kawecka-Jaszcz, K ;

Gessek, J ;

Wrabec, K .

CARDIOVASCULAR DRUGS AND THERAPY, 1999, 13 (03) :191-200

← 1 2 3 4 5 6 7 8 9 10 →